Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

RAPID

Financiado

RNA particles for Preparedness against Infectious Diseases

BunyaVax builds unprecedented technology for cost-effective and rapid development of vaccines against newly emerging viruses. The platform can be a valuable tool in quickly controlling the spread of new virus strains among populat... ver más

30/11/2018

BUNYAVAX

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

BUNYAVAX BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-11-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 6 años

0% 70% 100%

2 Participantes

BUNYAVAX

50.00K€ | Lider

T EL TREVOL 3028

499.95K€ | Participante

Últimas noticias

30-11-2024: Cataluña Gestión For... Se ha cerrado la línea de ayuda pública: Gestión Forestal Sostenible para Inversiones Forestales Productivas para el organismo:

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

Duración del proyecto: 6 meses Fecha Inicio: 2018-05-09
Fecha Fin: 2018-11-30

Líder del proyecto

BUNYAVAX BV

TRL 4-5

Presupuesto del proyecto 71K€

Descripción del proyecto BunyaVax builds unprecedented technology for cost-effective and rapid development of vaccines against newly emerging viruses. The platform can be a valuable tool in quickly controlling the spread of new virus strains among populations. The timing of RAPID closely corresponds with a current focus of the vaccine industry on novel vaccine platform technologies that enable rapid response to emerging threats. The BunyaVax RNA particle technology combines the efficacy of live vaccines with the safety of inactivated or subunit vaccines – which are currently the standard vaccine technologies. A unique characteristic of the RNA platform is that it allows for ‘plug and play’ application. Any gene can be plugged into the RNA particle genome to generate inherently safe and efficacious vaccines. The platform can stably express a broad variety of pathogen derived antigens. A major advantage is that development and manufacturing can be completed in a timeframe of 16 weeks which is at least twice as fast as current methods. The BunyaVax technology is in a stage of proven efficacy in sheep. RAPID is designed to prepare for partnerships with vaccine manufacturers and/or venture capital firms and to lay the foundation for clinical application of the vaccine platform. Key steps for upscaled production levels will be taken. The innovation project is at the core of the strategy of BunyaVax. The project is instrumental for reaching a stage in which commercial partnerships can be explored. Ultimately, this will allow BunyaVax to forward the technology to a stage in which industry can use it to develop vaccines for controlling veterinary and human infectious disease outbreaks at an earlier stage than currently possible.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores